# Curlim ## Posts - [Attending BioEquity Europe 2025](https://curlim.eu/attending-bioequity-europe-2025/): We’re thrilled to announce that CURLIM will be participating in BioEquity Europe 2025 as a presenting company!  This prestigious event is a key gathering for biotech leaders, investors, and innovators shaping the future of healthcare. The 2025 edition will take place from May 12 to 14 in Bruges, Belgium. Each year, BioEquity Europe spotlights carefully selected companies with high scientific potential and a clear roadmap toward clinical and commercial success. The event is designed to foster meaningful interactions — from formal presentations and one-on-one meetings to informal networking — all focused on advancing breakthrough science and improving patient outcomes. We’re looking forward […] ## Pages - [News](https://curlim.eu/news/) - [Our team](https://curlim.eu/our-team/): Our team Founders Laurent Richebourg Co-founder //CEO View profile Laurent Richebourg Co-founder, CEO With over 30 years of experience in the healthcare industry, Laurent has held C-level positions across medical imaging, in-vitro diagnostics, and hospital equipment in major companies such as Abbott, Danaher, J&J and Siemens. A graduate in biomedical engineering from the University of Technology of Compiègne (UTC) and in business from HEC, he worked closely with R&D and operations all along his career. His numerous responsibilities in general management, marketing, sales, finance, and after-sales, at both international and national levels, have provided him with essential tools for the successful management of a company. […] - [Proof of concept](https://curlim.eu/proof-of-concept/): Proof of concept – Initial Focus CMT1A – A pathology with no effective treatment to date CLM001 was developed to target Charcot-Marie-Tooth disease type 1A (CMT1A), the most common hereditary peripheral neuropathy, characterized by progressive motor disorders beginning in childhood. CMT1A is caused by a duplication of the PMP22 gene, leading to the overexpression of the PMP22 protein. This disrupts normal myelin formation and results in progressive peripheral nerve degeneration. To date, no therapy has demonstrated clinical efficacy, and millions of patients are still awaiting a curative solution. Successful preclinical studies Non-clinical studies were conducted in two animal models of […] - [Cookie Policy](https://curlim.eu/cookie-policy/): Cookie Policy This website uses cookies to optimize navigation, analyze usage anonymously, and ensure the proper functioning of key features. Cookies are small text files stored on your device when you visit a website. They help improve user experience by remembering your preferences and enabling basic functionalities. We use the following categories of cookies: 1. Functional Cookies Essential for enabling the use of specific services explicitly requested by the user (e.g., access to secure areas, language preferences). Without these cookies, certain features would not function properly. 2. Statistical Cookies Used exclusively to collect anonymous data for internal statistical purposes, such […] - [Privacy Policy](https://curlim.eu/privacy-policy/): Privacy policy 1. Introduction CURLIM attaches great importance to the protection of your personal data.This Privacy Policy explains how we collect, use, and protect the personal information you may provide through our website. 2. Data Controller The data controller is CURLIM, located at 1 avenue d’Ester, Ester Technopole, 87069 Limoges, France.For any questions regarding data protection, you can contact us at: info@curlim.eu. 3. Data Collected We may collect and process the following data: Identification data (e.g., name, email address) when you contact us Technical data (e.g., country, browser type) for site security and analytics 4. Purpose of Data Collection We […] - [Legal Notice](https://curlim.eu/legal-notice/): Legal Notice 1. Website Publisher The website www.curlim.eu is published by:CURLIM, a French SAS (Simplified Joint-Stock Company) with a capital of €177,798.00, registered under number 985 116 748 at the RCS of Limoges (France). Head office:1 avenue d’Ester, Ester Technopole, 87069 Limoges, France Director of publication: CEO of CURLIM Contact: info@curlim.eu 2. Website Hosting The website is hosted by: Hostinger International Ltd.61 Lordou Vironos, Larnaca 6023, CyprusWebsite: https://www.hostinger.com 3. Intellectual Property All elements of the website (texts, images, logos, graphics, downloadable documents, videos, etc.) are protected under French and international intellectual property laws.These elements are the exclusive property of CURLIM, unless […] - [Technology](https://curlim.eu/technology/): Technology behind CLM001 CLM001 is the result of a proprietary three-component nano-formulation, specifically engineered to deliver a curcumin-based active pharmaceutical ingredient (API) with maximum therapeutic potential. Our technology To overcome this, CLM001 leverages a smart and synergistic delivery platform composed of : A curcumin-based API With therapeutic action targeting key drivers of Charcot-Marie-Tooth disease type 1A (CMT1A). Cationic beta-cyclodextrins To encapsulate, solubilize, and protect the API, extending its bioavailability. Cellulose nanocrystals (CNCs) To act as a carrier, enabling intracellular delivery via a “Trojan Horse” mechanism. Encapsulation for Protection and Stability The curcumin-based API is encapsulated in cationic beta-cyclodextrins, a molecule […] - [Contact](https://curlim.eu/contact/): Contact us Get in touch For professional inquiries regarding our research, partnerships, or investment opportunities, please contact us using the information below. 1 Avenue d’Ester • 87280 LIMOGES info@curlim.eu Linkedin - [Home](https://curlim.eu/): Revolutionizing Neuropathy Treatment Through Cutting-Edge Nanodrug Innovation Discover our technology About Curlim Driven by unmet medical needs. Empowered by breakthrough science. Founded in 2024 as a spin-off from the University of Limoges, Curlim brings together three PhD scientists and a C-level Business person to tackle one of the biggest unmet needs in neurology: effective treatment for hereditary peripheral neuropathies. Our first mission: to develop a breakthrough therapy for Charcot-Marie-Tooth disease type 1A (CMT1A) — the most common hereditary neuropathy. Meet our team CLM001 A Breakthrough Nanodrug Targeting the Root Causes of CMT1A CLM001 is intended for the treatment of Charcot-Marie-Tooth […] [comment]: # (Generated by Hostinger Tools Plugin)